

Guocan Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6665200/publications.pdf>

Version: 2024-02-01

18
papers

3,529
citations

759233

12
h-index

888059

17
g-index

21
all docs

21
docs citations

21
times ranked

7497
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition. <i>Oncogene</i> , 2022, 41, 757-769.	5.9	12
2	A simple quantitative PCR assay to determine TRAMP transgene zygosity. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 358-361.	3.9	1
3	Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4. <i>IScience</i> , 2021, 24, 102388.	4.1	12
4	P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis. <i>Oncogene</i> , 2021, 40, 6049-6056.	5.9	19
5	Telomere dysfunction activates YAP1 to drive tissue inflammation. <i>Nature Communications</i> , 2020, 11, 4766.	12.8	42
6	Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer. <i>Cancer Discovery</i> , 2020, 10, 1374-1387.	9.4	60
7	A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 990-999.	7.0	11
8	The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. <i>Cancer Cell</i> , 2019, 36, 139-155.e10.	16.8	131
9	KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 35, 559-572.e7.	16.8	353
10	Î-Tocopherol inhibits the development of prostate adenocarcinoma in prostate specific Pten ^{+/+} mice. <i>Carcinogenesis</i> , 2018, 39, 158-169.	2.8	12
11	Genetics and biology of prostate cancer. <i>Genes and Development</i> , 2018, 32, 1105-1140.	5.9	434
12	Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 5137-5149.	8.2	269
13	Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. <i>Nature</i> , 2017, 542, 484-488.	27.8	173
14	Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. <i>Cancer Cell</i> , 2017, 32, 42-56.e6.	16.8	1,282
15	Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. <i>Cell</i> , 2016, 167, 1281-1295.e18.	28.9	207
16	Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. <i>Cancer Discovery</i> , 2016, 6, 80-95.	9.4	404
17	K63-Linked Ubiquitination in Kinase Activation and Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 5.	2.8	84
18	Targeting prostate cancer stem cells for cancer therapy. <i>Discovery Medicine</i> , 2012, 13, 135-42.	0.5	20